Safety and Efficacy of Mycophenolate Mofetil Associated With Tacrolimus for Kidney-pancreas and Kidney Transplantation: A Systematic Review and Meta-Analysis of Randomized Studies

他克莫司 医学 霉酚酸酯 荟萃分析 随机对照试验 肾移植 移植 肾 泌尿科 内科学
作者
Letícia Nogueira Datrino,M. Boccuzzi,Raoni de Oliveira Domingues da Silva,Pedro H. Castilho,Letícia Nogueira Datrino,Jéssica Silva Rocha,Francisco Tustumi
出处
期刊:Transplantation Proceedings [Elsevier BV]
卷期号:56 (5): 1066-1076
标识
DOI:10.1016/j.transproceed.2024.05.014
摘要

This study evaluated the efficacy and safety of mycophenolate mofetil (MMF) associated with tacrolimus (TAC) in patients undergoing kidney-pancreas and kidney transplants, in comparison with cyclosporine (CyA), azathioprine (AZA), everolimus (EVL), sirolimus (SRL), manitimus (MAN), mizoribine (MZR), and enteric-coated mycophenolate sodium (ECMPS) in combination or monotherapy. A systematic review and meta-analysis of randomized clinical trials was performed. The outcomes comprised acute rejection, graft loss, and adverse events. Thirty studies were included. The main adverse events related to the TAC+MMF scheme were infection (36%; 95%CI: 26%-46%), including cytomegalovirus (CMV) (14%; 95%CI: 8%-20%); anemia (20%; 95%CI: 2%-37%); leukopenia (18%; 95%CI: 3%-33%); nausea (20%; 95%CI: 1%-39%); and diarrhea (26%; 95%CI:13%-40%). TAC+MMF was compared to the schemes AZA+TAC, CyA+AZA, CyA+MMF, CyA+SRL, ECMPS, EVL, MAN+TAC, MMF+SRL, MZR, TAC+AZA, TAC+EVR, TAC+MZR, TAC +SRL and TAC. TAC+MMF was associated with a lower risk of rejection than MMF monotherapy (RD: -0.24; 95%CI -0.46; -0.02). Comparing TAC+MMF with the other regimens, no significant difference was found for graft loss. TAC+MMF was associated with a higher risk of infections than MZR (RD: 0.174; 95%CI: 0.25; 0.323) and TAC monotherapy (RD: 0.07; 95%CI 0.003; 0.138). Gastrointestinal and hematological adverse events and infections are the most common with TAC+MMF for kidney-pancreas and kidney. TAC+MMF effectively prevents acute cellular rejection, and alternatives with AZA, CyA, SRL, ECMPS, EVL, MAN, and MSR have similar efficacy and safety profiles. TAC monotherapy and MZR may be associated with a lower risk of infections.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LITM完成签到,获得积分10
刚刚
Wangjz发布了新的文献求助30
刚刚
晴儿发布了新的文献求助10
刚刚
SciGPT的应助被入司采纳,获得10
1秒前
英姑的应助被安居客采纳,获得10
1秒前
Kiutaka发布了新的文献求助10
1秒前
123完成签到,获得积分10
1秒前
祁郁郁发布了新的文献求助10
1秒前
嘻嘻哈哈的应助被HaoYongzeng采纳,获得10
1秒前
2秒前
zy完成签到 ,获得积分10
2秒前
cxc发布了新的文献求助10
2秒前
xingchy完成签到,获得积分10
2秒前
科目三的应助被rensuying采纳,获得10
3秒前
Xin关闭了Xin的文献求助
3秒前
LXR完成签到,获得积分10
3秒前
研友_VZG7GZ的应助被天行不息采纳,获得30
3秒前
李果完成签到 ,获得积分10
4秒前
TJJ完成签到,获得积分20
5秒前
洋洋得意完成签到,获得积分10
5秒前
文艺冰蝶完成签到,获得积分10
5秒前
Jelly完成签到,获得积分20
5秒前
5秒前
orixero的应助被可乐采纳,获得10
6秒前
冬冬完成签到,获得积分10
6秒前
20的应助被土木搬砖法律采纳,获得50
7秒前
上官若男的应助被xingchy采纳,获得10
7秒前
情怀的应助被XiaodongWang采纳,获得10
7秒前
Criminology34的应助被YYBAS采纳,获得10
8秒前
JamesPei的应助被YYBAS采纳,获得10
8秒前
8秒前
爆米花的应助被YYBAS采纳,获得10
8秒前
8秒前
蜜獾完成签到,获得积分20
9秒前
9秒前
11秒前
科目三的应助被小龙采纳,获得10
11秒前
11秒前
兴奋的问寒完成签到,获得积分10
11秒前
徐X发布了新的文献求助20
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8156693
求助须知:如何正确求助?哪些是违规求助? 9552815
关于积分的说明 21711665
捐赠科研通 7745741
什么是DOI,文献DOI怎么找? 3426606
关于科研通互助平台的介绍 2551406
邀请新用户注册赠送积分活动 2470452